News headlines about Akorn (NASDAQ:AKRX) have been trending positive recently, AlphaOne reports. The research firm, a service of Accern, rates the sentiment of press coverage by monitoring more than 20 million blog and news sources. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akorn earned a coverage optimism score of 0.36 on AlphaOne’s scale. AlphaOne also gave news stories about the company an impact score of 100 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the next several days.
Here are some of the news stories that may have impacted AlphaOne’s rankings:
- Coming Out Swinging, Shares of Akorn, Inc. (NASDAQ:AKRX), Realogy Holdings Corp. (NYSE:RLGY) Popping – Geneva Journal (genevajournal.com)
- Akorn Up 52.9% Since SmarTrend Uptrend Call (AKRX) (mysmartrend.com)
- The Akorn, Inc. (AKRX) Shares Sold by ProShare Advisors LLC – BangaloreWeekly (bangaloreweekly.com)
- Health News: Insider Trading Activity Opko Health Inc. (NASDAQ:OPK) – CEO Bought 27,800 shares of Stock (robinspost.com)
- Will Akorn Inc (AKRX) Continue To Underperform Its Industry? (simplywall.st)
Several analysts have commented on AKRX shares. Vetr upgraded shares of Akorn from a “buy” rating to a “strong-buy” rating and set a $23.96 target price on the stock in a report on Tuesday, January 24th. Jefferies Group LLC began coverage on shares of Akorn in a report on Tuesday, January 31st. They set a “buy” rating and a $24.00 target price on the stock. TheStreet raised shares of Akorn from a “c+” rating to a “b-” rating in a research note on Thursday, April 20th. Deutsche Bank AG cut shares of Akorn from a “buy” rating to a “hold” rating and decreased their price target for the stock from $28.00 to $24.00 in a research note on Monday, March 6th. Finally, WallachBeth Capital raised their price target on shares of Akorn from $22.00 to $25.00 and gave the stock a “hold” rating in a research note on Friday, March 10th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $30.55.
Akorn (NASDAQ:AKRX) opened at 33.21 on Friday. The company has a market capitalization of $4.14 billion, a PE ratio of 22.67 and a beta of 1.12. The firm’s 50-day moving average is $31.66 and its 200-day moving average is $24.08. Akorn has a 52-week low of $17.61 and a 52-week high of $35.40.
Akorn (NASDAQ:AKRX) last posted its quarterly earnings data on Wednesday, March 1st. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.01. Akorn had a return on equity of 38.59% and a net margin of 16.58%. The company had revenue of $283.70 million during the quarter, compared to analysts’ expectations of $287.91 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. Akorn’s revenue for the quarter was up 1.3% compared to the same quarter last year. On average, equities research analysts forecast that Akorn will post $1.62 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Akorn (AKRX) Getting Positive News Coverage, Report Finds” was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://transcriptdaily.com/2017/05/20/akorn-akrx-earning-favorable-press-coverage-analysis-finds-updated-updated.html.
Akorn Company Profile
Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.
Receive News & Ratings for Akorn Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn Inc. and related companies with MarketBeat.com's FREE daily email newsletter.